Abstract
BACKGROUND: This meta-analysis compared the diagnostic performance of [(18)F] fluorodeoxyglucose ([(18)F]FDG) positron emission tomography/computed tomography (PET/CT) or PET versus Magnetic resonance imaging (MRI) in detecting recurrence or residual tumors at the primary site in patients with nasopharyngeal carcinoma (NPC). METHODS: A comprehensive literature search was conducted in the PubMed/MEDLINE and CENTRAL databases to find studies with at least 20 patients with NPC undergoing both [(18)F]FDG PET/CT (or [(18)F]FDG PET) and MRI for detecting recurrence or assessing residual disease at the primary site. The pooled sensitivity and specificity of PET/CT and MRI were calculated with 95% confidence intervals (CIs) and compared. RESULTS: Five studies, including 1908 patients (six patient groups), were included. PET imaging had higher sensitivity [93.3% (95% CI: 91.3-94.9%); I(2) = 52.6%] compared to MRI [80.1% (95% CI: 77.2-82.8%); I(2) = 68.3%], but the specificity of the two modalities was similar: 93.8% (95% CI: 92.2-95.2%; I(2) = 0%) for PET/CT and 91.8% (95% CI: 90.1-93.4%; I(2) = 94.3%) for MRI. The areas under the curve (AUCs) for PET/CT and MRI were 0.978 and 0.924, respectively, without significant difference (p = 0.23). CONCLUSIONS: This meta-analysis suggests that [(18)F]FDG PET imaging and MRI do not significantly differ in diagnostic performance. Nevertheless, [(18)F]FDG PET imaging shows higher sensitivity than MRI.